Literature DB >> 12005350

Novel effect of CP55,940, a CB1/CB2 cannabinoid receptor agonist, on intracellular free Ca2+ levels in bladder cancer cells.

Chung-Ren Jan1, Yih-Chau Lu, Bang-Ping Jiann, Hong-Tai Chang, Warren Su, Wei-Chung Chen, Jong-Khing Huang.   

Abstract

The study was undertaken to explore the effect of CP55,940 ((-)-cis-3-[2-Hydroxy4-(1,1-dimethylheptyl) phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol), a drug commonly used as a CB1/CB2 cannabinoid receptor agonist, on intracellular free Ca2+ levels ([Ca2+]i) in several cell types [Ca2+]i was measured in suspended cells by using the fluorescent dye fura-2 as an indicator. At concentrations between 1-50 microM, CP55,940 increased [Ca2+]i in a concentration-dependent manner with an EC50 of 8 microM. The [Ca2+]i signal comprised an initial rise, a slow decay, and a sustained phase. CP55940 (10 microM)-induced (Ca2+]i signal was not altered by 5 microM of two cannabinoid receptor antagonists (AM-251, N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; AM-281, 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-m3thyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide). Extracellular Ca2+ removal decreased the maximum value of the Ca2+ signals by 50%. CPS5,940 (10 microM)-induced [Ca2+]i increase in Ca2+-free medium was inhibited by 80% by pretreatment with 1 microM thapsigargin, an endoplasmic reticulum Ca2+ pump inhibitor. Conversely, pretreatment with 10 microM CP55,940 in Ca2+-free medium for 6 min abolished thapsigargin-induced [Ca2+]i increase. Nifedipine (10 microM) and verapamil (10 microM) did not alter CP55,940 (10 microM)-induced [Ca2+]i increase. CP55, 940 (10 microM)-induced Ca2+ release was not affected when phospholipase C was inhibited by 2 microM U73122 (1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione). CP55,940 (5 microM) also increased [Ca22+] in Madin-Darby canine kidney cells, MG63 human osteosarcoma cells, and IMR-32 neuroblastoma cells. Collectively, CP,55940 induced significant [Ca2+]i increases in several cell types by releasing store Ca2+ from thapsigargin-sensitive pools and by causing Ca2+ entry. The CP55,940's action appears to be dissociated from stimulation of cannabinoid receptors

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12005350

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  5 in total

1.  Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines.

Authors:  Iain Brown; Maria G Cascio; Klaus W J Wahle; Reem Smoum; Raphael Mechoulam; Ruth A Ross; Roger G Pertwee; Steven D Heys
Journal:  Carcinogenesis       Date:  2010-07-25       Impact factor: 4.944

2.  Cannabinoid receptor subtype 2 (CB2R) agonist, GW405833 reduces agonist-induced Ca(2+) oscillations in mouse pancreatic acinar cells.

Authors:  Zebing Huang; Haiyan Wang; Jingke Wang; Mengqin Zhao; Nana Sun; Fangfang Sun; Jianxin Shen; Haiying Zhang; Kunkun Xia; Dejie Chen; Ming Gao; Ronald P Hammer; Qingrong Liu; Zhengxiong Xi; Xuegong Fan; Jie Wu
Journal:  Sci Rep       Date:  2016-07-19       Impact factor: 4.379

3.  Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca2+ signals of mouse pancreatic acinar cells in vitro.

Authors:  Kun-Kun Xia; Jian-Xin Shen; Ze-Bing Huang; Hui-Min Song; Ming Gao; De-Jie Chen; Shui-Jun Zhang; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2018-09-10       Impact factor: 6.150

Review 4.  The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory.

Authors:  Mohammed I Khan; Anna A Sobocińska; Anna M Czarnecka; Magdalena Król; Bruno Botta; Cezary Szczylik
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

5.  Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma.

Authors:  Francesca Punzo; Chiara Tortora; Daniela Di Pinto; Iolanda Manzo; Giulia Bellini; Fiorina Casale; Francesca Rossi
Journal:  Oncotarget       Date:  2017-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.